3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Cyclophosphamide
48
fludarabine
32
Methotrexate
26
blinatumomab
20
Dexamethasone
20
fludarabine phosphate
19
Vincristine
19
Whole-Body Irradiation
17
Specimen Handling
17
Cytarabine
17
Tacrolimus
15
Peripheral Blood Stem Cell Transplantation
14
Mycophenolic Acid
14
Melphalan
13
Calcium Dobesilate
12
Busulfan
12
Biopsy
12
merphos
11
Mercaptopurine
11
Stem Cell Transplantation
10
Granulocyte Colony-Stimulating Factor
10
Etoposide
10
Cyclosporine
10
Thiotepa
9
Rituximab
9
Magnetic Resonance Spectroscopy
9
Doxorubicin
9
venetoclax
8
ponatinib
8
dexamethasone acetate
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Cobicistat
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA